The Ohio State University Comprehensive Cancer Center (OSUCCC) Pharmacoanalytical Shared Resource (PhASR) has been in development since 2004. PhASR provides bioanalytical method development, quantitative sample analysis, and pharmacokinetic/pharmacodynamic (PK/PD) experimental design and data analysis to support pre-clinical and clinical cancer drug development. PhASR's objectives are to provide: 1) high-quality, state-of-the-art analytical expertise and instrumentation for quantitation of drugs and metabolites in biological specimens at cost-competitive rates;2) PK/PD data for incorporation into clinical decision-making;and 3) expertise in PK/PD study design and data interpretation to support submission of clinical protocols, grants, and publications. PhASR is directed by Dr. Kenneth K. Chan, with additional support from Technical Director, Dr. Mitch A. Phelps. An additional staff of 2.70 full-time employees provides support for sample processing, method development and PK/PD data analysis and modeling. Outstanding institutional support is provided by the OSUCCC and College of Pharmacy's Division of Pharmaceutics that houses the fully-equipped pharmaceutical research laboratories of Drs Chan and Phelps which comprise PhASR. Major equipment in PhASR includes 3 LC-MS systems and 2 stand-alone LC-UV systems ideally suited for drug quantitation and metabolite identification. These systems include a quadrupole-time-of-flight and two triple-quadrupole mass spectrometers, one of which is supported by an ultra-high pressure liquid chromatography system expandable for automated sample processing and high throughput enalysis. Additional LC-MS systems to develop and run biological correlative assays are available. By leveraging outstanding institutional partnerships, PhASR is able to offer its services to OSUCCC members at reduced rates. In the past 12 months PhASR staff has analyzed more than 2,600 samples and has logged nearly 1,700 hours for analytical method development and PK/PD experimental design and data analysis. Neariy 95% of this activity supported 27 members in 5 of the 6 programs within the OSUCCC. Recent highlights of work by PhASR researchers include design of an active flavopiridol dosing schedule and pharmacokinetic modeling of data from 8 clinical trials;development, validation and application of ultrasensitive assays (pM) to support clinical investigations of Bcl-2 and ribonucleotide reductase targeted antisense therapies (G3139 and GTI-2040);validation and application of methods for quantitation of low dose decitabine and resulting intracellular endogenous nucleoside and drug phosphates and global and regional DNA methylation;and pre-clinical pharmacokinetic and metabolism studies of the novel natural product, silvestrol, now in pre-clinical development by the OSUCCC and the NCI. In its short time as a developing resource, PhASR has made these and other significant contributions resulting in high impact publications, grant proposals and funding for OSUCCC investigators. Institutional support and OSUCCC investigators'recognition of the quality of PhASR capabilities and services have insured the continued growth and success of this highly valued shared resource.

Public Health Relevance

Ohio State University Comprehensive Cancer Center (OSUCCC) Pharmacoanalytical Shared Resource (PhASR) provides cost effective, high quality and state-of-the-art bioanalytical method development quantitative sample analysis, and pharmacokinetic/pharmacodynamic experimental design and data analysis to support pre-clinical and clinical cancer drug development

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-37
Application #
8567319
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-12-01
Budget End
2013-11-30
Support Year
37
Fiscal Year
2013
Total Cost
$118,161
Indirect Cost
$40,678
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Salem, Galena; Ruppert, Amy S; Elder, Patrick et al. (2015) Lower dose of antithymocyte globulin does not increase graft-versus-host disease in patients undergoing reduced-intensity conditioning allogeneic hematopoietic stem cell transplant. Leuk Lymphoma 56:1058-65
Niederwieser, C; Kohlschmidt, J; Volinia, S et al. (2015) Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia. Leukemia 29:567-75
Billingsley, Caroline C; Cohn, David E; Mutch, David G et al. (2015) Polymerase ? (POLE) mutations in endometrial cancer: clinical outcomes and implications for Lynch syndrome testing. Cancer 121:386-94
Krok-Schoen, Jessica L; Kurta, Michelle L; Weier, Rory C et al. (2015) Clinic type and patient characteristics affecting time to resolution after an abnormal cancer-screening exam. Cancer Epidemiol Biomarkers Prev 24:162-8
Biddle, Martha J; Lennie, Terry A; Bricker, Gregory V et al. (2015) Lycopene dietary intervention: a pilot study in patients with heart failure. J Cardiovasc Nurs 30:205-12
Jin, Ming; Roth, Rachel; Rock, Jonathan B et al. (2015) The impact of tumor deposits on colonic adenocarcinoma AJCC TNM staging and outcome. Am J Surg Pathol 39:109-15
Llanos, Adana A; Pennell, Michael L; Young, Gregory S et al. (2015) No association between colorectal cancer worry and screening uptake in Appalachian Ohio. J Public Health (Oxf) 37:322-7
Nguyen, Huyen T; Jia, Guang; Shah, Zarine K et al. (2015) Prediction of chemotherapeutic response in bladder cancer using K-means clustering of dynamic contrast-enhanced (DCE)-MRI pharmacokinetic parameters. J Magn Reson Imaging 41:1374-82
Berman-Booty, Lisa D; Thomas-Ahner, Jennifer M; Bolon, Brad et al. (2015) Extra-prostatic transgene-associated neoplastic lesions in transgenic adenocarcinoma of the mouse prostate (TRAMP) mice. Toxicol Pathol 43:186-97
Durmus, Kasim; Patwa, Hafiz S; Gokozan, Hamza N et al. (2014) Functional and quality-of-life outcomes of transoral robotic surgery for carcinoma of unknown primary. Laryngoscope 124:2089-95

Showing the most recent 10 out of 1178 publications